Table 3 Antipsychotic monotherapy used in the maintenance treatment and readmission rate of patients followed-up from 2012 to 2017, BrasÃlia—Brazil
Antipsychotic group | Antipsychotic | Frequency, No. (%) | Readmission, No. (%) |
|---|---|---|---|
N = 518 | |||
Typical (oral) | Chlorpromazine | 30 (5.8) | 22 (73.3) |
Haloperidol | 281 (54.2) | 199 (70.8) | |
Levomepromazine | 11 (2.1) | 6 (54.5) | |
Thioridazine | 4 (0.8) | 1 (25.0) | |
Total | 326 (62.9) | 228 (69.9) | |
Atypical (oral) | Aripiprazole | 15 (2.9) | 9 (60.0) |
Quetiapine | 31 (6.0) | 18 (58.1) | |
Clozapine | 13 (2.5) | 7 (53.8) | |
Risperidone | 66 (12.7) | 33 (50.0) | |
Olanzapine | 19 (3.7) | 9 (47.4) | |
Total | 144 (27.8) | 76 (52.8) | |
LAIs1 | Depot Risperidone | 6 (1.2) | 5 (83.3) |
Depot Haloperidol | 42 (8.1) | 29 (69.0) | |
Total | 48 (9.3) | 34 (70.8) | |
Total | Â | 518 (100) | 338 (65.2) |